Evidence map›Paper›PMID 38517650›Full record

ArticleInvestigational new drugs2024

Association between albumin-bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients.

Kazuma Fujita, Daiki Taguchi, Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Hanae Shinozaki, Hiroyuki Shibata, Masatomo Miura

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigational new drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Baseline hypoalbuminemia enhances regorafenib-induced problematic fatigue development in real-world metastatic colorectal cancer treatment.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kazuma FujitaDepartment of Pharmacy, Akita University Hospital, Akita, Japan.
Daiki TaguchiDepartment of Clinical Oncology, Akita University, Akita, Japan.
Koji FukudaDepartment of Clinical Oncology, Akita University, Akita, Japan.
Taichi YoshidaDepartment of Clinical Oncology, Akita University, Akita, Japan.
Kazuhiro ShimazuDepartment of Clinical Oncology, Akita University, Akita, Japan.
Hanae ShinozakiDepartment of Clinical Oncology, Akita University, Akita, Japan.
Hiroyuki ShibataDepartment of Clinical Oncology, Akita University, Akita, Japan.
Masatomo MiuraDepartment of Pharmacy, Akita University Hospital, Akita, Japan. m-miura@hos.akita-u.ac.jp.
Akita University · JPAkita University Hospital · JP

Funding

Japan Society for the Promotion of Science 23H05274
6 · The paper itself

Abstract

The aim of the present study was to determine whether the trough plasma concentrations (C

Indexed as

BilirubinPhenylurea CompoundsPyridinesAdultAgedAged, 80 and overAntineoplastic AgentsEast Asian PeopleFemaleHumansJapanJapanese peopleMaleMiddle AgedSerum AlbuminAntineoplastic AgentsBilirubinPhenylurea CompoundsPyridinesregorafenibSerum AlbuminAlbumin–bilirubin gradeM-2M-5Overall survivalPlasma concentrationRegorafenib

Identifiers

PMID38517650
PMCPMC11164767
OpenAlexW4393092840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.